Innovative Medicines Initiative Launches 100th Project
The Innovative Medicines Initiative (IMI) has launched its 100th project in the form of Hypo-RESOLVE, a 4 year, EUR 26.8 million project on diabetes. The milestone comes as IMI celebrates its 10th anniversary with a series of events and activities. The IMI project portfolio is diverse; many projects, like Hypo-RESOLVE, focus on specific health issues such as diabetes, neurological conditions (including dementia, depression, and pain), cancer, auto-immune diseases (such as rheumatoid arthritis), and infectious diseases (including antimicrobial resistance and Ebola).
Source: eHealth News EU - Category: Information Technology Tags: Featured Development Research and Development Source Type: news
More News: Antimicrobial Resistance | Arthritis | Brain | Cancer | Cancer & Oncology | Dementia | Depression | Diabetes | Ebola | Endocrinology | Infectious Diseases | Information Technology | Neurology | Pain | Rheumatoid Arthritis | Rheumatology